IO Biotech (IOBT) said Thursday it completed enrollment ahead of schedule in a phase 2 trial of its cancer vaccine candidate IO102-IO103 combined with Merck's (MRK) Keytruda to treat people with resectable melanoma or squamous cell carcinoma of the head and neck.
Initial data is expected this year, the company said.
The trial has enrolled 93 people in the US, Europe and Australia, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments